OCT 14, 2021 8:00 AM PDT

'Bio-Betters' Form the Next Wave of Cancer Therapies

WRITTEN BY: Tara Fernandes


 

Antibodies are blood proteins with highly specialized functions: to recognize and eliminate bacteria, viruses, and other foreign substances in the body. Inspired by the exquisite specificity of these molecules, drug developers have been turning them into therapies for a range of diseases, including cancer. 

The first approved monoclonal antibody to treat blood cancers (a drug called rituximab) paved the way for a long line of similar biologics to enter the clinic. The problem, however, is that these therapies don't work for all patients. Additionally, in the patients who respond, the cancer-killing effects of antibody treatments wane over time as tumors develop resistance. 

Due to these limitations, researchers have been seeking ways of enhancing cancer biologics. Recent work by scientists at the University of Southampton, in collaboration with biopharma partner UCB, has seen a breakthrough in the field—engineered antibodies with a unique 2-in-1 feature for combating cancer. 

The new platform combines distinctive properties of two antibody classes, IgM and IgG, to improve the therapeutic effectiveness of the resulting hybrid antibody. A modified IgM' tailpiece' is fused to the C-terminus of IgG. This addition of the C757S-tailpiece—a small, 18 amino-acid peptide—activates the complement pathway to enhance target cell killing while limiting adverse side effects in patients. The innovators of the method see this as a plug-and-play tool where the tailpiece can be engineered onto existing antibodies, turning them into what they call 'bio-betters'.

Lead researcher Mark Cragg from the University of Southampton said, "Antibody engineering is a fascinating area and allows us to take advantage of the fantastic molecules that nature has evolved to combat infection and improve on them for our therapeutic purposes."

 

 



 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
FEB 08, 2022
Health & Medicine
Promising New Myasthenia Gravis Drug Completes Phase 3 Trial
FEB 08, 2022
Promising New Myasthenia Gravis Drug Completes Phase 3 Trial
Zilucoplan, a peptide inhibitor under investigation for the treatment of generalized myasthenia gravis in adults, was fo ...
MAR 04, 2022
Clinical & Molecular DX
A New Indicator of Disease Severity for Muscular Dystrophy
MAR 04, 2022
A New Indicator of Disease Severity for Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy (FSHD), a genetic disorder causing loss of muscular function, primarily impacts t ...
FEB 20, 2022
Health & Medicine
Effective Covid-19 Multidrug Treatment Using Repurposed Time-Tested and Inexpensive Drugs
FEB 20, 2022
Effective Covid-19 Multidrug Treatment Using Repurposed Time-Tested and Inexpensive Drugs
Ivermectin has been a drug of controversy in the COVID-19 treatment debate. Last year, it got a bad rap from the mainstr ...
MAR 22, 2022
Health & Medicine
Back to Nature: the Health Benefits of Nature Prescriptions
MAR 22, 2022
Back to Nature: the Health Benefits of Nature Prescriptions
With modern amenities and luxuries, it's easy to be unaware of just how much we may neglect the outdoors and its hea ...
APR 29, 2022
Immunology
Mental Health and Our Immune System
APR 29, 2022
Mental Health and Our Immune System
The conversation regarding mental health is finally at the forefront and is no longer a taboo topic that people shy away ...
MAY 15, 2022
Immunology
Long-Term Antibiotics Raise the Risk of Death From a Systemic Fungal Infection
MAY 15, 2022
Long-Term Antibiotics Raise the Risk of Death From a Systemic Fungal Infection
Infections are common, and many are becoming increasingly hard for clinicians to treat. Antibiotics are often used to tr ...
Loading Comments...